Evidence map›Paper›PMID 29419396›Full record

ArticleDisease models & mechanisms2018

Expanding primary cells from mucoepidermoid and other salivary gland neoplasms for genetic and chemosensitivity testing.

Ahmad M Alamri, Xuefeng Liu, Jan K Blancato, Bassem R Haddad, Weisheng Wang, Xiaogang Zhong, Sujata Choudhary, Ewa Krawczyk, Bhaskar V Kallakury, Bruce J Davidson and 1 more

Abstract read
In one paragraph

Article in Disease models & mechanisms, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Conditional Cell Reprogramming in Modeling Digestive System Diseases.Frontiers in cell and developmental biology · 2021
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ahmad M AlamriOncology, Georgetown University, Washington, DC 20057, USA.
Xuefeng LiuPathology, Center for Cell Reprogramming, Georgetown University, Washington, DC 20057, USA.
Jan K BlancatoOncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Bassem R HaddadOncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Weisheng WangOncology, Georgetown University, Washington, DC 20057, USA.
Xiaogang ZhongBiostatistics, Bioinformatics and Biomathematics, Georgetown University, Washington, DC 20057, USA.
Sujata ChoudharyPathology, Georgetown University, Washington, DC 20057, USA.
Ewa KrawczykPathology, Center for Cell Reprogramming, Georgetown University, Washington, DC 20057, USA.
Bhaskar V KallakuryPathology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Bruce J DavidsonOtolaryngology - Head and Neck Surgery, MedStar Georgetown University Hospital, Washington, DC 20007, USA.
Priscilla A FurthOncology and Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA paf3@georgetown.edu.ORCID 0000-0003-3883-0715

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI MARCUS S NOEL · 1990 to 2026
$71.5M
Mechanisms Regulating Reversal of Premalignancy and Threapuetic SensitivityR56DE023259 · NIDCR · GEORGETOWN UNIVERSITY · PI FURTH, PRISCILLA A. · 2012 to 2012
$194k
NCI NIH HHS P30 CA051008NIDCR NIH HHS R56 DE023259
6 · The paper itself

Abstract

Restricted availability of cell and animal models is a rate-limiting step for investigation of salivary gland neoplasm pathophysiology and therapeutic response. Conditionally reprogrammed cell (CRC) technology enables establishment of primary epithelial cell cultures from patient material. This study tested a translational workflow for acquisition, expansion and testing of CRC-derived primary cultures of salivary gland neoplasms from patients presenting to an academic surgical practice. Results showed that cultured cells were sufficient for epithelial cell-specific transcriptome characterization to detect candidate therapeutic pathways and fusion genes, and for screening for cancer risk-associated single nucleotide polymorphisms (SNPs) and driver gene mutations through exome sequencing. Focused study of primary cultures of a low-grade mucoepidermoid carcinoma demonstrated amphiregulin-mechanistic target of rapamycin-protein kinase B (AKT; AKT1) pathway activation, identified through bioinformatics and subsequently confirmed as present in primary tissue and preserved through different secondary 2D and 3D culture media and xenografts. Candidate therapeutic testing showed that the allosteric AKT inhibitor MK2206 reproducibly inhibited cell survival across different culture formats. By contrast, the cells appeared resistant to the adenosine triphosphate competitive AKT inhibitor GSK690693. Procedures employed here illustrate an approach for reproducibly obtaining material for pathophysiological studies of salivary gland neoplasms, and other less common epithelial cancer types, that can be executed without compromising pathological examination of patient specimens. The approach permits combined genetic and cell-based physiological and therapeutic investigations in addition to more traditional pathologic studies, and can be used to build sustainable bio-banks for future inquiries.This article has an associated First Person interview with the first author of the paper.

Indexed as

Antineoplastic AgentsCarcinoma, MucoepidermoidCell DifferentiationCell ProliferationCell SurvivalCulture Media, ConditionedGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansNeoplasm ProteinsProtein Kinase InhibitorsSalivary Gland NeoplasmsSignal TransductionTranscriptomeTumor Cells, CulturedXenograft Model Antitumor AssaysAntineoplastic AgentsCulture Media, ConditionedNeoplasm ProteinsProtein Kinase InhibitorsAKTDrug sensitivityMucoepidermoid carcinomaNext-generation sequencingPrimary cell cultureSalivary gland neoplasms

Identifiers

PMID29419396
PMCPMC5818080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.